Bio-Rad Laboratories, Inc. Announces Pricing of Public Offering of $425 Million Senior Notes

HERCULES, CA--(Marketwire - December 06, 2010) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today the pricing of $425 million aggregate principal amount of 4.875% senior notes due 2020 (the “Senior Notes”) in connection with a public offering pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. The Company intends to close the transaction on December 9, 2010. The Company intends to use the proceeds from this offering, together with cash on hand, to redeem all $225 million of its outstanding 7.50% senior subordinated notes due 2013 and all $200 million of its outstanding 6.125% senior subordinated notes due 2014.

Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering of the Senior Notes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Senior Notes or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a prospectus and the related prospectus supplement. Copies of the prospectus and related prospectus supplement regarding the offering of the Senior Notes may be obtained from Bio-Rad Laboratories, Inc. at 1000 Alfred Nobel Drive, Hercules, California, 94547 or from Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include statements about the offering of the Senior Notes and our intent to redeem certain of our outstanding senior subordinated notes and are based on our current expectations. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.